Novo Nordisk remains coy over Wegovy blockbuster potential
Sales of Novo Nordisk’s newest obesity treatment, Wegovy, have been steadily increasing since its summer launch. Despite this, Novo CEO Lars Fruergaard Jørgensen remains silent on the drug’s blockbuster potential.
by christopher due karlsson, translated by daniel pedersen
With last Friday’s release of Novo Nordisk’s quarterly report for 2021, the pharmaceutical firm chose to reveal the actual sales figures for obesity drug Wegovy for the first time.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk unveils Wegovy sales
For subscribers
Novo Nordisk subsupplier reinitiates Wegovy production
For subscribers
